Belpointe Asset Management LLC Amgen Inc Transaction History

Belpointe Asset Management LLC

$1.51 Billion
Q4 2024

A detailed history of Belpointe Asset Management LLC transactions in Amgen Inc stock. As of the latest transaction made, Belpointe Asset Management LLC holds 9,760 shares of AMGN stock, worth $3.07 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

9,760

Previous 8,122 20.17%

Holding current value

$3.07 Million

Previous $2.62 Million 2.79%

% of portfolio

0.17%

Previous 0.18%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$258.78 - $328.31 $423,881 - $537,771	1,638 Added 20.17%	9,760 $2.54 Million
Q3 2024 Nov 12, 2024	BUY	$309.38 - $337.38 $571,115 - $622,803	1,846 Added 29.41%	8,122 $2.62 Million
Q2 2024 Aug 02, 2024	SELL	$262.75 - $319.31 $110,880 - $134,748	-422 Reduced 6.3%	6,276 $1.96 Million
Q1 2024 May 08, 2024	SELL	$268.87 - $324.56 $270,214 - $326,182	-1,005 Reduced 13.05%	6,698 $1.9 Million
Q4 2023 Feb 13, 2024	SELL	$255.7 - $288.46 $377,668 - $426,055	-1,477 Reduced 16.09%	7,703 $2.22 Million
Q3 2023 Nov 15, 2023	BUY	$218.65 - $271.46 $359,460 - $446,280	1,644 Added 21.82%	9,180 $2.47 Million
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $369,401 - $436,809	-1,724 Reduced 18.62%	7,536 $1.67 Million
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $685,046 - $834,956	3,034 Added 48.73%	9,260 $2.24 Million
Q4 2022 Feb 08, 2023	BUY	$229.03 - $291.01 $58,631 - $74,498	256 Added 4.29%	6,226 $1.64 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $158,468 - $178,723	706 Added 13.41%	5,970 $1.35 Million
Q2 2022 Aug 02, 2022	SELL	$230.71 - $256.74 $185,952 - $206,932	-806 Reduced 13.28%	5,264 $1.28 Million
Q1 2022 Apr 28, 2022	BUY	$219.27 - $242.57 $139,894 - $154,759	638 Added 11.75%	6,070 $1.47 Million
Q4 2021 Feb 15, 2022	BUY	$198.88 - $227.6 $114,952 - $131,552	578 Added 11.91%	5,432 $1.22 Million
Q3 2021 Nov 15, 2021	SELL	$212.27 - $248.7 $152,197 - $178,317	-717 Reduced 12.87%	4,854 $1.03 Million
Q2 2021 Aug 09, 2021	BUY	$233.58 - $259.14 $298,515 - $331,180	1,278 Added 29.77%	5,571 $1.36 Million
Q1 2021 May 14, 2021	SELL	$221.91 - $258.6 $338,190 - $394,106	-1,524 Reduced 26.2%	4,293 $1.07 Million
Q4 2020 Feb 16, 2021	BUY	$216.38 - $257.67 $182,624 - $217,473	844 Added 16.97%	5,817 $1.34 Million
Q3 2020 Nov 13, 2020	SELL	$234.65 - $260.95 $141,024 - $156,830	-601 Reduced 10.78%	4,973 $1.26 Million
Q3 2020 Nov 13, 2020	BUY	$234.65 - $260.95 $93,860 - $104,380	400 Added 7.73%	5,574 $1.13 Million
Q2 2020 Jul 20, 2020	SELL	$197.81 - $242.74 $79,124 - $97,096	-400 Reduced 7.18%	5,174 $1.22 Million
Q1 2020 Jul 20, 2020	SELL	$182.24 - $241.7 $383,615 - $508,778	-2,105 Reduced 27.41%	5,574 $1.13 Million
Q4 2019 Feb 18, 2020	BUY	$189.21 - $243.2 $582,577 - $748,812	3,079 Added 66.93%	7,679 $1.85 Million
Q3 2019 Jan 16, 2020	BUY	$174.11 - $208.62 $78,349 - $93,879	450 Added 10.84%	4,600 $890,000
Q2 2019 Nov 22, 2019	SELL	$166.7 - $195.41 $466,093 - $546,366	-2,796 Reduced 40.25%	4,150 $0
Q1 2019 Jun 11, 2019	BUY	$180.87 - $203.88 $198,233 - $223,452	1,096 Added 18.74%	6,946 $1.32 Million
Q4 2018 Mar 06, 2019	BUY	$178.4 - $208.25 $453,314 - $529,163	2,541 Added 76.79%	5,850 $1.14 Million
Q3 2018 Nov 23, 2018	BUY	$185.29 - $208.89 $224,571 - $253,174	1,212 Added 57.8%	3,309 $686,000
Q2 2018 Aug 06, 2018	SELL	$166.05 - $186.51 $123,873 - $139,136	-746 Reduced 26.24%	2,097 $387,000
Q1 2018 Aug 06, 2018	BUY	$169.43 - $198.0 $74,718 - $87,318	441 Added 18.36%	2,843 $485,000
Q4 2017 Feb 15, 2018	SELL	$168.79 - $188.59 $17,047 - $19,047	-101 Reduced 4.04%	2,402 $418,000
Q3 2017 Nov 16, 2017	BUY	$167.29 - $191.0 $418,726 - $478,073	2,503	2,503 $467,000

Others Institutions Holding AMGN

# of Institutions

3,183

Shares Held

419M

Call Options Held

8.25M

Put Options Held

6.39M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $168B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belpointe Asset Management LLC with notifications on news.

Account

Belpointe Asset Management LLC Amgen Inc Transaction History